Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
MALVERN, Pa., May 09, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Due to technical difficulties experienced by NASDAQ during today’s call, management has rescheduled its conference call for 6:00 PM ET today to discuss the Company’s financial results and provide a general business update. The conference will be webcast live over the Internet and can be accessed by logging on to the “Investors” section of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. A replay of the webcast will be archived on the Company’s website for 30 days following the call.
To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 5101760 prior to the start of the call.
About Aclaris
Aclaris Therapeutics, Inc. is a clinical-stage dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.
Contact: Aclaris Contact Michael Tung, M.D. Investor Relations 484-329-2140 [email protected] Media Contact Mariann Caprino TogoRun 917-242-1087 [email protected]
